

Explore Our Active Clinical Trials*

Tap on a trial to learn more



Investigating Established Agents in New Treatment Areas or Settings

BRENTUXIMAB VEDOTIN ^a	ENFORTUMAB VEDOTIN ^b	TUCATINIB	TISOTUMAB VEDOTIN ⁱ
Diffuse large B-cell lymphoma ECHELON-3 3L+	Locally advanced or metastatic urothelial cancer EV-302/KEYNOTE-A39^c 1L	HER2+ breast cancer CompassHER2 RD^d EBC	Recurrent or metastatic cervical cancer innovaTV 301 2L+
Hodgkin lymphoma and CD30+ peripheral T-cell lymphoma SGN35-015 1L	Cisplatin-ineligible/decline muscle invasive bladder cancer KEYNOTE-905/EV-303^d Perioperative	HER2+ breast cancer HER2CLIMB-02 2L	Advanced solid tumors innovaTV 207ⁱ 1L, 2L+
Early and advanced stage Hodgkin lymphoma SGN35-027 1L	Cisplatin-eligible muscle invasive bladder cancer KEYNOTE-B15/EV-304^d Perioperative	HER2+ breast cancer HER2CLIMB-05^h 1L	Recurrent or metastatic cervical cancer innovaTV 205ⁱ 2L+
CD30-low and -negative peripheral T-cell lymphoma SGN35-032 1L	Locally advanced or metastatic solid tumors EV-202 2L+	HER2+ colorectal cancer MOUNTAINEER-03^h 1L	
Metastatic non-small cell lung cancer and melanoma SGN35-033 1L, 2L	Locally advanced or metastatic urothelial cancer KEYMAKER-U04^e 1L	HER2+ breast cancer HER2CLIMB-04 2L+	
AYA CD30+ Hodgkin lymphoma CHECKMATE 744 2L	Locally advanced or metastatic urothelial cancer KEYMAKER-U04^e 1L	Locally advanced or metastatic solid tumors with HER2 alterations SGNTUC-019 2L+	
	Urothelial cancer EV-103/KEYNOTE-869^f Various settings	HER2+ gastrointestinal cancers SGNTUC-024 1L+	
	BCG-unresponsive non-muscle invasive bladder cancer EV-104 Intravesical EV		

Late-Stage ADCs

DISITAMAB VEDOTIN	SGN-B6A
Urothelial cancer with HER2 expression SGNDV-001^k 1L	Previously treated non-small cell lung cancer SGNB6A-002 2L+
Urothelial cancer with HER2 expression RC48 G001ⁱ 2L+	Advanced solid tumors SGNB6A-001 1L/1L+
Locally advanced or metastatic solid tumors with HER2 expression SGNDV-005 2L+	

Early-Stage ADCs

SGN-ALPV	SGN-B7H4V	SGN-PDL1V	SGN-STNV
Advanced solid tumors SGNALPV-001 2L+	Advanced solid tumors SGNB7H4V-001 2L+	Advanced solid tumors SGNPDL1V-001 2L+	Advanced solid tumors SGNSTNV-001 2L+

Other Targeted Modalities

SGN-BB228	SGN-EGFRd2	SEA-CD70	SEA-TGT
Advanced melanoma and solid tumors SGNBB228-001 2L+	Advanced solid tumors SGNEGFRd2-001 2L+	Myelodysplastic syndrome and acute myeloid leukemia SGNS70-101 1L+	Advanced solid tumors and lymphomas SGNTGT-001 1L/1L+

Seagen Technology

- Antibody-drug conjugate (ADC)
- Small molecule
- Bispecific antibody
- Sugar-engineered antibody (SEA)



Line of therapy

1L: first line
2L: second line
3L: third line

*The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

AYA: adolescents and young adults; BCG: bacillus Calmette-Guérin; CD: cluster of differentiation; EBC: early breast cancer; HER2: human epidermal growth factor receptor 2
^aProgram being co-developed with Takeda Pharmaceutical Company, Ltd.; ^bProgram being co-developed with Astellas Pharma Global Development, Inc.; ^cStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD). Enrolling in a China-specific extension only; ^dStudy sponsored by MSD, in collaboration with Seagen Inc. and Astellas Pharma Global Development, Inc.; ^eStudy sponsored by MSD; Substudy 04B of KEYMAKER-U04 umbrella study; ^fStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and MSD; ^gTrial being conducted by the Alliance for Clinical Trials in Oncology; ^hTrial being co-developed with MSD; ⁱProgram being co-developed with Genmab A/S; ^jTrial in collaboration with MSD; ^kTrial in collaboration with Remegen Co., Ltd. and MSD
 Seagen and its logo are US registered trademarks of Seagen Inc. Other trademarks are property of their respective owners.
 © 2023 Seagen Inc., Bothell, WA 98021. All rights reserved. USM/GEN/2023/0041, MA-MM-06973 Sep 2023